Drug intelligence / Profile preview

BSC4101

Development stage: Preclinical
Lead developer: BiSiChem
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Parenteral

Overview

BSC4101 is an antibody-drug conjugate (ADC) being developed by BiSiChem for the treatment of an undisclosed indication. The drug is currently in early research and discovery phases, with development activity reported in South Korea. As of the latest updates, its mechanism of action and specific therapeutic target have not been disclosed. It is classified as a new molecular entity and has not received orphan drug designation[1][2].

Other names: BSC 4101BSC4101BSC-4101

Beyond the preview

Go deeper on BSC4101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC4101.

Explore the full profile